A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

Psychological stress is known to exacerbate skin allergies, but the underlying molecular mechanisms remain poorly understood.

About the TEBE-AM Phase 3 registrational trial with tebentafusp in previously treated advanced cutaneous melanoma The trial is randomizing ... bispecific protein comprised of a soluble T cell receptor ...

Fintel reports that on January 13, 2025, D. Boral Capital initiated coverage of Checkpoint Therapeutics (NasdaqCM:CKPT) with ...

Denileukin diftitox is under clinical development by Citius Oncology and currently in Phase II for Endometrial Cancer.

1H 2025: Preliminary data readout of Cohort 3 of ARTISTRY-6, an evaluation of a less-frequent intravenous (LFIV) dose of nemvaleukin monotherapy in patients with cutaneous melanoma ... the ...